Diaxonhit SA Stock Euronext Paris
Stocks
ALEHT
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Euronext Paris
|
||
| - EUR | - |
|
| Market Cap | 209M 242M 197M 179M 336M 23.19B 342M 2.31B 902M 11.61B 910M 891M 38.58B | P/E 2026 * |
18.4x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 177M 205M 167M 152M 285M 19.64B 290M 1.95B 764M 9.84B 771M 755M 32.69B | EV / Sales 2026 * |
1.01x | EV / Sales 2027 * | - |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 2023-06-12 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 2023-10-09 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 2023-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 2018-12-31 | |
Michel Picot
BRD | Director/Board Member | 73 | 2019-06-26 |
| Director/Board Member | 69 | 2017-06-14 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.78% | -1.68% | +1.48% | +15.31% | 48.42B | |
| +0.85% | -0.70% | +460.88% | +563.55% | 43.66B | |
| -2.40% | -0.23% | +8.13% | +71.41% | 39.51B | |
| -2.01% | -0.85% | +23.85% | +8.73% | 38.95B | |
| -0.50% | +0.85% | +20.60% | +49.65% | 32.61B | |
| +0.38% | -3.23% | - | - | 16.32B | |
| -0.59% | -2.06% | +26.35% | +118.09% | 16.15B | |
| +0.49% | +0.92% | +4.11% | +23.67% | 14.16B | |
| -0.43% | +4.70% | +78.74% | +33.31% | 13.37B | |
| Average | -0.67% | +0.49% | +78.02% | +110.46% | 29.24B | |
| Weighted average by Cap. | -0.91% | +0.59% | +95.83% | +132.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 176M 204M 165M 150M 283M 19.47B 287M 1.94B 757M 9.75B 765M 748M 32.41B | - |
| Net income | 11.6M 13.43M 10.9M 9.91M 18.64M 1.28B 18.95M 128M 49.94M 643M 50.43M 49.33M 2.14B | - |
| Net Debt | -32M -37.05M -30.07M -27.35M -51.41M -3.54B -52.26M -352M -138M -1.77B -139M -136M -5.9B | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ALERS Stock
- ALEHT Stock
Select your edition
All financial news and data tailored to specific country editions
